Scott Michael Palmer, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Vice-Chair for Research in the Department of Medicine
Professor in Immunology
Professor in Population Health Sciences
Core Faculty in Innovation & Entrepreneurship
Campus mail 2085 Msrb2 2 Genome Ct, Durham, NC 27710
Phone (919) 684-0245
Email address scott.palmer@duke.edu

Dr. Palmer leads a successful program of clinical, basic and translational research in transplantation and advanced lung diseases. He currently directs the pulmonary research program at the Duke Clinical Research Institute (DCRI) and serves as Vice Chair for Research in the Department of Medicine.

Dr. Palmer has over 150 peer reviewed publications, received numerous awards, including election into the American Society for Clinical Investigation (ASCI) in 2012, chaired many sessions at national and international meetings, serves regularly on NIH study sections, and is on the editorial board of many prominent journals. He is also Associate Director of the Clinical Research Training Program at Duke and has personally mentored over 40 pre-and post-doctoral trainees, many of whom are now engaged in their own successful research careers.

His scientific accomplishments include the first human studies to demonstrate the importance of innate immunity in transplant rejection and completion of a prospective multicenter study that improved CMV prevention after lung transplantation.

Current basic projects in the lab are studying the role of the matrix in the activation of innate immunity in pulmonary transplant rejection, and epithelial injury and repair in the development of toxin induced bronchiolitis obliterans. Translational and human projects are studying predictors of lung transplant survival in the UNOS database, immune monitoring to predict CMV infection and acute rejection after lung transplantation, and the use of novel inhaled antibiotics in lung transplantation. The lab is also using cutting edge whole exome genetic sequencing to identify genetic predictors of transplant rejection.

Dr. Palmer also leads trials coordinated through the DCRI that study the natural history and investigate new treatments for idiopathic pulmonary fibrosis (IPF), chronic lung transplant rejection, and posttransplant cytomegalovirus infection.

Education and Training

  • Fellow, Pulmonary Medicine, Medicine, Duke University, 1996 - 1999
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.H.S., Duke University, 2000
  • M.D., Duke University, 1993

Publications

Smith, P. J., J. A. Blumenthal, B. M. Hoffman, R. D. Davis, and S. M. Palmer. “Postoperative cognitive dysfunction and mortality following lung transplantation..” Am J Transplant 18, no. 3 (March 2018): 696–703. https://doi.org/10.1111/ajt.14570.

PMID
29087035
Full Text

Riley, Isaretta L., L Ebony Boulware, Jie-Lena Sun, Karen Chiswell, Loretta G. Que, Monica Kraft, Jamie L. Todd, Scott M. Palmer, and Monique L. Anderson. “Factors associated with reporting results for pulmonary clinical trials in ClinicalTrials.gov..” Clin Trials 15, no. 1 (February 2018): 87–94. https://doi.org/10.1177/1740774517740352.

PMID
29121787
Full Text

Shaver, Ciara M., Nancy Wickersham, J Brennan McNeil, Hiromasa Nagata, Adam Miller, Stuart R. Landstreet, Jamie L. Kuck, et al. “Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury..” Jci Insight 3, no. 2 (January 25, 2018). https://doi.org/10.1172/jci.insight.98546.

PMID
29367464
Full Text

Cantu, Edward, Joshua M. Diamond, Yoshikazu Suzuki, Jared Lasky, Christian Schaufler, Brian Lim, Rupal Shah, et al. “Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction after Lung Transplant..” Am J Respir Crit Care Med 197, no. 2 (January 15, 2018): 235–43. https://doi.org/10.1164/rccm.201706-1140OC.

PMID
28872353
Full Text

Palmer, S. M., L. Snyder, M. L. Neely, E. Yow, S. Bender, D. A. Culver, J. de Andrade, et al. “Survival in Patients with Idiopathic Pulmonary Fibrosis (IPF): Data from the IPF-PRO Registry.” In American Journal of Respiratory and Critical Care Medicine, Vol. 197. AMER THORACIC SOC, 2018.

Scholars@Duke

Clark, R., N. C. Gaddis, J. L. Levy, M. Duparc, H. Pan, G. P. Page, J. A. Whitsett, and S. M. Palmer. “BREATH: An Open-Access Database of Normal Lung Development Generated by the Molecular Atlas of Lung Development Program (LungMAP).” In American Journal of Respiratory and Critical Care Medicine, Vol. 197. AMER THORACIC SOC, 2018.

Scholars@Duke

Weigt, S., X. Wang, V. Palchevskiy, N. D. Patel, D. J. Ross, Y. M. Shino, J. M. Reynolds, et al. “Gene Expression Profiling of BAL Cells and PBMC During Lung Allograft Acute Cellular Rejection.” In American Journal of Respiratory and Critical Care Medicine, Vol. 197. AMER THORACIC SOC, 2018.

Scholars@Duke

Anderson, M. R., E. Edwin, J. M. Diamond, J. P. Singer, T. Blue, M. Oyster, L. Kalman, et al. “Intrathoracic Adipose Gene Expression and Primary Graft Dysfunction After Lung Transplantation.” In American Journal of Respiratory and Critical Care Medicine, Vol. 197. AMER THORACIC SOC, 2018.

Scholars@Duke

Ardini-Poleske, Maryanne E., Robert F. Clark, Charles Ansong, James P. Carson, Richard A. Corley, Gail H. Deutsch, James S. Hagood, et al. “LungMAP: The Molecular Atlas of Lung Development Program..” Am J Physiol Lung Cell Mol Physiol 313, no. 5 (November 1, 2017): L733–40. https://doi.org/10.1152/ajplung.00139.2017.

PMID
28798251
Full Text

Porteous, Mary K., James C. Lee, David J. Lederer, Scott M. Palmer, Edward Cantu, Rupal J. Shah, Scarlett L. Bellamy, et al. “Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension..” Ann Am Thorac Soc 14, no. 10 (October 2017): 1514–22. https://doi.org/10.1513/AnnalsATS.201610-810OC.

PMID
28719755
Full Text

Pages